The data used in the study are derived from a deidentified NCDB file. The American College of Surgeons and the Comission on Cancer have not verified and are not responsible for the analytic or statistical methodology used, or the conclusions drawn from these data by the investigators.
See JNCCN.org for supplemental online content.
Edge SB BD, Compton CC, Fritz AG et al., eds. American Joint Committee on Cancer Staging Manual, 7th ed. New York, NY: Springer; 2010.
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997;350:1647–1654.
Pervaiz N, Colterjohn N, Farrokhyar F et al.. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008;113:573–581.
Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 2008;15:683–690.
Rosenbaum PR, Rubin DB. The Central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41–55.
Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399–424.
Xu S, Ross C, Raebel MA et al.. Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health 2010;13:273–277.
Xie J, Liu C. Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. Stat Med 2005;24:3089–3110.
Jones RL, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer 2005;41:2853–2860.
Zagars GK, Ballo MT, Pisters PW et al.. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer 2003;97:2530–2543.
Coindre JM, Terrier P, Guillou L et al.. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001;91:1914–1926.
Frustaci S, Gherlinzoni F, De Paoli A et al.. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001;19:1238–1247.
Frustaci S, De Paoli A, Bidoli E et al.. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 2003;65(Suppl 2):80–84.
Canter RJ, Qin LX, Maki RG et al.. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clinical Can Res 2008;14:8191–8197.
Eilber FC, Brennan MF, Eilber FR et al.. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg 2007;246:105–113.
Eilber FC, Eilber FR, Eckardt J et al.. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg 2004;240:686–695; discussion 695–697.
Cormier JN, Huang X, Xing Y et al.. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol 2004;22:4567–4574.